In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

Experimental Hematology

Volumn 30, Issue 7, 2002, Pages 729-737

  La Rosée, Paul ^a,b   Johnson, Kara ^a   O'Dwyer, Michael E ^a   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BCR ABL PROTEIN; CASPASE 3; IMATINIB;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ARSENICALS; CASPASE 3; CASPASES; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; OXIDES; PIPERAZINES; PYRIMIDINES; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY;

EID: 0036320754     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00836-6     Document Type: Article

References (49)

1. The biology of chronic myeloid leukemia
2. The molecular biology of chronic myeloid leukemia
3. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
4. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
5. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
6. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
7. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study
8. TM (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: Results of a phase II study
9. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
10. Roots of clinical resistance to STI-571 cancer therapy
11. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
12. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
13. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
14. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells
15. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells
16. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
17. A phase I study of the combination of Gleevec (imatinib mesylate) with low dose ara-C
18. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose interferon-α for the treatment of chronic phase CML
19. PEGIntron and STI571 Combination Evaluation Study (PISCES) in chronic phase chronic myeloid leukaemia
20. Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
21. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)
22. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
23. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells
24. Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features
25. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
26. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL
27. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
28. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
29. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines
30. Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage
31. The search for synergy: A critical review from a response surface perspective
32. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
33. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
34. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells
35. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia?
36. What is synergy?
37. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity
38. Role of modelling in joint action studies
39. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
40. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells
41. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of Bcl-2 protein
42. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
43. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
44. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells
45. Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells
46. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts
47. Mechanism by which arsenic trioxide downregulates Bcr-Abl levels and potentiates Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells
48. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy
49. Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype